Casey Tansey
General Partner @ U.S. Venture Partners
Menlo Park, United States
Casey Tansey is a Series D investor at U.S. Venture Partners in Menlo Park focused on Health Care and Medical Device. Casey Tansey joined USVP as a general partner in April 2005. A veteran of the medical device industry, Casey brings over 25 years of entrepreneurial, early-stage medical device and seasoned operating experience to USVP. Casey's extensive operations experience brings more to the table than strategic counsel -- he adds empathy to that mix.Casey's investment strategy is a lot like his strategy as a CEO: identify unmet clinical needs where patients are in need of new and improved products and services. At USVP, Casey focuses on the trend toward the miniaturization of devices and the development of minimally-invasive technologies that promise innovations in the delivery of medical products and services, especially in cardiovascular products, orthopedics, spinal care and neurology. Casey's passion is to strive for delivery of medical services with less trauma to the patient and improved quality of life. Innovations shaping this trend include minimally-invasive technologies. During his tenure as CEO and President of Epicor Medical from 2001 to 2004, Casey, along with a dedicated team, pioneered a minimally-invasive treatment for atrial fibrillation and transformed the company into a recognized market leader, and he led Epicor's acquisition by St. Jude Medical. Prior to Epicor, Casey was CEO and President of Heartport, a public company that helped pioneer minimally-invasive cardiac surgery which is now a Johnson & Johnson company. Before that, he was with Baxter Edward's Cardiovascular Division for nearly ten years, holding various sales and marketing positions. During his tenure at Baxter, Casey was involved in launching innovative heart valve products that have grown to be the market leaders. Casey serves on the Board of Directors for ApniCure, CardioKinetix, Devax, Inspire Medical, Intersect ENT, Intuity Medical, ReShape Medical, and SentreHEART. In addition, he served as the Chairman of the Board of Directors of the World Heart Foundation, an organization dedicated to advancing humanitarian efforts in heart surgery worldwide through education and collaboration. Casey holds a B.S. and M.B.A. from the College of Notre Dame in Belmont, CA. Casey has served on the boards of Epicor Medical and Heartport.
- Total investments:
- 24
- Last investment:
- Lead investor:
- 46%
Last updated:
For AI agents: llms.txt
Industries Casey Tansey invests in
Stages Casey Tansey invests in
Countries Casey Tansey invests in
Investment Focus
Industry
- Health Care 14 (58%)
- Medical Device 11 (46%)
- Medical 8 (33%)
- Biotechnology 6 (25%)
- Wellness 2 (8%)
Stage
- Series D 4 (17%)
- Series A 3 (13%)
- Series C 3 (13%)
- Series E 3 (13%)
- Series B 2 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cagent Vascular
|
Cagent Vascular is a medical device company developing minimally invasive technologies to treat cardiovascular disease. | $41M / Series D / May 19, 2026 | |
Iantrek
|
Iantrek develops technology for minimally invasive microinvasive glaucoma surgery. It was founded in 2019 and is based in White Plains, New York. | $42M / Series C / Aug 20, 2025 | |
Neuros Medical
|
Neuros Medical is a neuromodulation company, is focused on developing proprietary therapies for the unmet needs of patients worldwide. The Company's patented platform technology, Electrical Nerve Block, is focused on the elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post-surgicalpain, and chronic migraine. | $56M / Series D / Jul 09, 2025 | |
Heartflow
|
HeartFlow is the leader in revolutionizing precision heart care, uniquely combining human ingenuity with advanced technology. HeartFlow’s non-invasive HeartFlow FFRCT Analysis leverages artificial intelligence to create a personalized three-dimensional model of the heart. Clinicians can use this model to evaluate the impact a blockage has on bloodflow and determine the best treatment for patients. HeartFlow’s technology is reflective of our Silicon Valley roots and incorporates over two decades of scientific evidence with the latest advances in artificial intelligence. The HeartFlow FFRCT Analysis is commercially available in the United States, UK, Canada, Europe and Japan. For more information, visit www.heartflow.com. | $98M / Convertible Note / Mar 26, 2025 | |
Mobia Medical
|
MicroTransponder is a medical device company that develops and commercializes neurostimulation devices to treat neurological diseases. Its therapies include paired vagus nerve stimulation system (Paired VNS System) and wireless neurostimulation system for the treatment of chronic pain, post-stroke upper limb mobility issues, and variousneurological indications that enable healthcare practitioners to treat post-stroke upper limb mobility issues.Founded in 2007, MicroTransponder is headquartered in Dallas, Texas. | $65M / Series F / Mar 12, 2025 | |
Shoulder Innovations
|
Shoulder Innovations is a medical device company that has developed inset glenoid fixation technology, creating the most robust and stable glenoid platform in the industry. The company's Total Shoulder Replacement System addresses the most significant issue in shoulder arthroplasty: unreliable fixation of the glenoid implant. It also leveragesthis technology to create simple surgical instrumentation, which reduces operative time and cost.Shoulder Innovations designs and commercializes innovative products that demonstrate the potential for improved patient care and reduced overall cost to the healthcare system. Published results show Shoulder Innovations’ solution provides greater post-surgical implant stability, addressing the leading cause of revision surgery. | $40M / Series E / Mar 10, 2025 | |
|
Cagent Vascular
|
Cagent Vascular is a medical device company developing minimally invasive technologies to treat cardiovascular disease. | $30M / Series C / Feb 20, 2024 | |
Luminopia
|
Luminopia develops a new class of treatments for significant neuro-visual disorders. The company is committed to creating digital therapeutics that are both rigorously evaluated for FDA approval and genuinely engaging for patients. As an Innovation Partner of Boston Children’s Hospital, the company is developing its lead product, Luminopia One, totreat amblyopia, the cause of vision loss among children. | $16M / Series A / Jun 27, 2023 | |
|
Mobia Medical
|
MicroTransponder is a medical device company that develops and commercializes neurostimulation devices to treat neurological diseases. Its therapies include paired vagus nerve stimulation system (Paired VNS System) and wireless neurostimulation system for the treatment of chronic pain, post-stroke upper limb mobility issues, and variousneurological indications that enable healthcare practitioners to treat post-stroke upper limb mobility issues.Founded in 2007, MicroTransponder is headquartered in Dallas, Texas. | $73M / Series E / Jun 20, 2022 | |
Standard Bariatrics
|
Standard Bariatrics is a medical device company that develops and offers surgical instruments for weight-loss surgeries.The company offers Standard Clamp, an instrument that helps surgeons standardize their individual techniques to reduce variation, improve efficiency, and eliminate waste when performing a laparoscopic sleeve gastrectomy.Standard Bariatrics was founded in 2014 and is based in Cincinnati, Ohio. | $35M / Series B / Jun 01, 2021 | |
| See all 24 investments → | |||
Co-Investors
About U.S. Venture Partners
U.S. Venture Partners (USVP) is a venture capital partnership, helping entrepreneurs transform their ideas and efforts into world-changing companies. The firm focuses on early-stage ventures in information technology and health care, where innovation is unbridled and has led to the creation of economic wealth and millions of jobs over the pastthirty-plus years of the firm's existence. Areas of particular interest to our investment professionals include enterprise software, IT security, consumer internet, mobile, and e-commerce, healthcare, and IT-enabled healthcare services. The USVP team consists of former entrepreneurs, technologists, corporate executives, financial professionals, and industry domain experts.
U.S. Venture Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Phil Young
Senior Advisor
|
|||
|
Casey Tansey
General Partner
|
|||
Dafina Toncheva
General Partner
|
|||
Dale Holladay
CPA/CFO
|
|||
Jacques Benkoski
General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Casey Tansey invest in?
Casey Tansey invests primarily in Health Care, Medical Device and Medical startups, most often at Series D and Series A stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Casey Tansey last invest?
The most recent investment recorded for Casey Tansey closed in May 2026. Shizune tracks 24 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
